导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.02% | 1028/4773 |
| 近一周 | -2.25% | 1595/5462 |
| 近一月 | -5.44% | 3229/5421 |
| 近一季 | -5.33% | 1813/5209 |
| 近半年 | -4.83% | 2639/4920 |
| 近一年 | 12.18% | 861/4366 |
| 近两年 | 76.48% | 855/2954 |
| 近三年 | 45.85% | 611/2253 |
| 成立以来 | 38.57% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.06% 809/4961 |
13.32% 2027/5312 |
- - |
- - |
| 2025 | 32.54% 1173/4813 |
3.48% 1079/3635 |
2.59% 1475/4076 |
21.49% 1783/4524 |
2.76% 857/4813 |
| 2024 | 8.51% 1543/3463 |
-0.67% 1137/2808 |
-4.52% 1518/3014 |
13.73% 2123/3129 |
0.60% 1190/3463 |
| 2023 | -6.26% 826/2656 |
5.86% 749/2280 |
-3.43% 796/2385 |
-4.69% 1204/2515 |
-3.80% 790/2655 |
| 2022 | -17.92% 640/2207 |
-11.31% 500/1919 |
3.10% 1216/2016 |
-11.33% 526/2113 |
1.24% 1331/2208 |
| 2021 | 14.54% 328/1822 |
3.28% 189/1255 |
9.58% 543/1330 |
1.34% 453/1466 |
-0.13% 1204/1822 |
| 2020 | - - |
- - |
- - |
- - |
-1.89% 1117/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中加中证500指数增强C VS. 长安沪深300非周期A(740101) |